Johnson & Johnson (NYSE:JNJ) Shares Sold by Sawyer & Company Inc

Sawyer & Company Inc lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,476 shares of the company’s stock after selling 906 shares during the quarter. Johnson & Johnson makes up about 1.7% of Sawyer & Company Inc’s holdings, making the stock its 17th largest position. Sawyer & Company Inc’s holdings in Johnson & Johnson were worth $3,993,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson in the third quarter valued at $27,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson during the third quarter worth about $37,000. Tower View Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its holdings in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth about $48,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.4 %

JNJ stock opened at $157.96 on Thursday. The stock has a market capitalization of $380.65 billion, a P/E ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The company has a 50 day moving average price of $158.76 and a two-hundred day moving average price of $156.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the previous year, the company earned $2.35 EPS. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were issued a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s payout ratio is 34.47%.

Analysts Set New Price Targets

Several equities analysts have issued reports on JNJ shares. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Raymond James raised their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $177.31.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.